Neoadjuvant chemotherapy and cytoreductive surgery in epithelial ovarian cancer

Table 1 Studies of cancer antigen 125 for predicting the result of surgery in epithelial ovarian cancer

First author, year	n	Preoperative CA 125 (U/mL)		Optimal surgery3	Sensitivity	Specificity	PPV	NPV
		Median	Cut-off
Not clinically useful1
Gemer et al[30], 2001	40	341	500	60%	62%	83%	71%	77%
Cooper et al[31], 2002	112	893	500	58%	49%	77%	74%	52%
Memarzadeh et al[32], 2003	99	-	912	73%	58%	54%	78%	31%
Rossi et al[33], 2004	822	1351	500	40%	40%	64%	-	-
Alcázar et al[34], 2004	67	730	620	48%	60%	-	-	-
Gemer et al[35], 2005	424	495	400	57%	69%	57%	55%	71%
Everett et al[36], 2005	56	NA	500	52%	-	-	-	-
Barlow et al[37], 2006	164	364	500	47%	66%	59%	64%	36%
Gilani et al[38], 2007	90	500	500	47%	68%	62%	64%	35%
Arits et al[39], 2008	96	625	330	43%	80%	42%	-	-
Chi et al[40], 2009	277	731	500	80%	-	-	-	-
Probably clinically useful1
Chi et al[41], 2000	100	819	500	45%	78%	73%	78%	73%
Saygili et al[42], 2002	92	494	500	52%	73%	77%	75%	75%
Obeidat et al[43], 2004	40	467	500	55%	72%	73%	68%	76%
Eltabbakh et al[44], 2004	72	680	500	81%	73%	74%	-	-
Brockbank et al[45], 2004	77	397	586	68%	80%	89%	86%	80%
Vorgias et al[46], 2009	426	650	500	42%	79%	90%	85%	85%

¹Studies of not clinical useful and probably useful were arranged according to the comments of the authors in each study;

²Diagnostic functions of cancer antigen (CA) 125 in the study were of the whole group (22% early stages and 78% advanced stages) while the numbers of patients (n) in other studies were of stage III or stage III-IV disease;

³All studies defined residual disease ≤ 1 cm as optimal surgery. NPV: Negative predictive value; PPV: Positive predictive value; NA: Not available.